Drug intelligence / Profile preview

GastimunHP

Development stage: Discontinued
Lead developer: Theratechnologies
Modality: Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

GastimunHP is a combination product designed to support the treatment of peptic ulcer disease associated with Helicobacter pylori (H. pylori) infection. It combines Lactobacillus johnsonii (L. johnsonii), a probiotic, and Immunoglobulin Y (IgY). L. johnsonii and IgY have demonstrated the ability to reduce the amount and activity of H. pylori in the human stomach, thereby aiming to improve the clearance of the bacterium and enhance patient tolerance to H. pylori treatment regimens. The product was investigated in a clinical trial for its effectiveness in improving H. pylori clearance over six to eight weeks of treatment and mitigating side effects.

Other names: GastimunHp Plus

Beyond the preview

Go deeper on GastimunHP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GastimunHP.

Explore the full profile